Myeloid cell-specific ablation of Runx2 gene exacerbates post-infarct cardiac remodeling

Masashi Tomimatsu1, Kotaro Matsumoto1, Moe Ashizuka1, Shohei Kumagai1, Shota Tanaka1, Takafumi Nakae1, Kosei Yokota1, Shunsuke Kominami1, Ryota Kajira1, Daisuke Okuzaki2, Daisuke Motooka2, Aki Shiraishi3, Takaya Abe3, Hideo Matsuda4, Yoshiaki Okada1, Makiko Maeda5,6, Shigeto Seno4, Masanori Obana1,7,8,9 & Yasushi Fujio1,7,9

Runt-related transcription factor 2 (Runx2), a regulator of osteoblast differentiation, is pathologically involved in vascular calcification; however, the significance of Runx2 in cardiac homeostasis remains unclear. Here, we investigated the roles of Runx2 in cardiac remodeling after myocardial infarction (MI). The expression of Runx2 mRNA and protein was upregulated in murine hearts after MI. Runx2 was expressed in heart-infiltrating myeloid cells, especially in macrophages, at the border zone of post-infarct myocardium. To analyze the biological functions of Runx2 in cardiac remodeling, myeloid cell-specific Runx2 deficient (CKO) mice were exposed to MI. After MI, ventricular weight/tibia length ratio was increased in CKO mice, concomitant with severe cardiac dysfunction. Cardiac fibrosis was exacerbated in CKO mice, consistent with the upregulation of collagen 1a1 expression. Mechanistically, immunohistochemical analysis using anti-CD31 antibody showed that capillary density was decreased in CKO mice. Additionally, conditioned culture media of myeloid cells from Runx2 deficient mice exposed to MI induced the tube formation of vascular endothelial cells to a lesser extent than those from control mice. RNA-sequence showed that the expression of pro-angiogenic or anti-angiogenic factors was altered in macrophages from Runx2-deficient mice. Collectively, Runx2+ myeloid cells infiltrate into post-infarct myocardium and prevent adverse cardiac remodeling, at least partially, by regulating endothelial cell function.

Myocardial infarction (MI) is one of the leading causes of heart failure (HF). Following ischemia and/or reperfusion injury at the acute phase, cardiomyocyte loss and fibrosis are observed during the subacute to the chronic phase, known as adverse cardiac remodeling. Since neurohumoral factors, such as adrenergic signals and renin–angiotensin–aldosterone system, are involved in cardiac remodeling, blockade of these factors is clinically recommended as pharmacotherapies against HF. Recently, much attention has been paid to the inflammation as a critical event for cardiac remodeling. As a result, it has been revealed that various kinds of inflammatory cells play important roles in the progression/prevention of post-infarct cardiac remodeling, suggesting that the modulation of inflammatory signaling pathways could be a novel therapeutic strategy.

Immediately after MI, neutrophils infiltrate into the heart and evoke the inflammation, followed by the infiltration of macrophages. So far, the M1/M2 classification has been applied to heart-infiltrating macrophages. M1 macrophages produce pro-inflammatory cytokines and exacerbate myocardial inflammation at an early stage. Afterwards, macrophages are phenotypically modulated into M2 macrophages and produce anti-inflammatory cytokines and growth factors, contributing to wound healing. Importantly, accumulating evidence has
demonstrated that heart-infiltrating macrophages cannot be classified simply into conventional subsets according to M1/M2 theory. Therefore, the characterization of myeloid cells by detailed analyses of gene expression profile is essential to understand the mechanism of cardiac remodeling.

Recent advances in osteoimmunology have demonstrated that bone-related genes are closely associated with inflammation. For example, osteopontin, which was originally identified as an adhesion molecule in bone tissue, is related with cardiac inflammation in experimental animal models and patients with dilated cardiomyopathy. Runt-related transcription factor 2 (Runx2) is a master gene responsible for osteoblast differentiation and bone formation. Interestingly, Runx2 is expressed not only in osteoblasts but also in a wide range of cell-lineages. In cardiovascular diseases, pathological expression of Runx2 results in vascular calcification by promoting differentiation of macrophages into osteoclast-like cells. However, the pathophysiological significance of Runx2 in cardiac remodeling remains to be fully elucidated.

In the present study, to clarify the biological significance of Runx2 in cardiac remodeling after MI, we employed murine coronary ligation model. The expression of Runx2 mRNA and protein was upregulated in post-infarct myocardium. Runx2 was expressed in heart-infiltrating CD11b+ myeloid cells, including macrophages. Myeloid cell-specific Runx2 gene ablation exacerbated cardiac function and fibrosis, associated with reduced capillary density, after MI. Consistently, tube formation assay showed that conditioned culture media of myeloid cells from Runx2 deficient mice exposed to MI exhibited reduced angiogenic activity. Moreover, myeloid cell-specific Runx2 gene ablation affected the production of pro-/anti-angiogenic factors in macrophages. This is the first demonstration that myeloid Runx2 is a critical regulator that prevents cardiac remodeling in post-infarct myocardium.

Results

Runx2 is expressed in myeloid cells that infiltrate into post-infarct myocardium. To address whether Runx2 is involved in cardiac remodeling, the cardiac expression of Runx2 mRNA was evaluated after MI by quantitative RT-PCR (Fig. 1A). The expression of Runx2 mRNA peaked 4 to 7 days after MI and gradually declined. Consistently, immunoblot analysis with anti-Runx2 antibody revealed that the expression of Runx2 protein was upregulated after MI (Fig. 1B,C). Next, we divided the infarced hearts into two areas after MI, infarct area and remote area, and analyzed the expression of Runx2 by qRT-PCR (Fig. 1D,E). Runx2 mRNA was highly expressed in infarct area, compared with remote area. Consistently, immunohistochemical analysis revealed that the infiltrating cells were positively stained with anti-Runx2 antibody at the border zone of post-infarct myocardium (Fig. 2A). Since the infiltrating cells mainly consist of myeloid cells, we examined whether heart-infiltrated myeloid cells express Runx2 by FACS analysis. More than 70% of CD45+ infiltrating cells were positively stained with anti-CD11b antibody (myeloid marker) 7 days after MI. Importantly, about 20% of CD11b were positively stained with anti-Runx2 antibody (Fig. 2B). As macrophages are major myeloid cells that infiltrate into myocardium 4–7 days after MI, the heart sections were co-stained with anti-Runx2 and anti-CD68 (macrophage marker) antibodies (Fig. 2C). Importantly, a large population of Runx2-positive cells were also stained with anti-CD68 antibody. Since Runx2+ CD68- cells were also observed in border and infarct area of infarcted myocardium, where fibrosis develops, Runx2 expression in myofibroblasts was investigated (Supplementary Fig. S1). Immunofluorescence staining with anti-Runx2 and anti-periostin (myofibroblast marker) antibodies demonstrated that Runx2 was also expressed in myofibroblasts; however, since the ratio of Runx2+periostin+ cells to Runx2+ cells was small, we focused on Runx2 which is expressed in myeloid cells. Since macrophages are classified into M1 and M2 subsets, we examined which subset expresses Runx2 using the antibodies against CD86 or CD206, M1 or M2 marker, respectively (Fig. 2D,E) and found that both M1 and M2 macrophages expressed Runx2.

Myeloid cell-specific Runx2 ablation deteriorated adverse cardiac remodeling after MI. To determine the functional roles of Runx2 in cardiac function, myeloid cell-specific Runx2 conditional knockout (Runx2 CKO) mice were generated by crossbreeding Runx2fl/fl mice with LysM-Cre mice. (Fig. 3A). Runx2fl/fl mice were used as controls. CD11b+ F4/80+ macrophages were sorted from Runx2fl/fl and Runx2 CKO hearts 7 days after MI, and the protein expression of Runx2 was assessed using immunoblotting. Runx2 was verified to be remarkably diminished in macrophages (Fig. 3B,C). To assess the effects of Runx2 ablation on the baseline phenotype, peripheral blood was collected from non-MI mice, and then, the number of various leukocyte subsets was measured. Myeloid cell-specific Runx2 ablation didn’t affect the number of neutrophils, monocytes, eosinophils and basophils, but reduced that of lymphocytes (Supplementary Fig. S2). Importantly, gravimetric analysis and echocardiographic showed that Runx2 depletion in myeloid cells didn’t affect baseline cardiac growth and function (Supplementary Fig. S3, Table1).

To elucidate the effects of Runx2 on the progression of cardiac remodeling, MI was generated in control and Runx2 CKO mice. Echocardiographic examination revealed that cardiac dysfunction was accelerated in Runx2 CKO mice 14 days after MI, compared with control mice (Table 1). Consistently, ventricular or lung weight normalized to tibia length was significantly increased in Runx2 CKO mice (Fig. 3D,E). Masson’s trichrome staining revealed that myeloid cell-specific Runx2 ablation increased fibrotic area (Fig. 3F,G). Consistently, qPCR demonstrated that Runx2 CKO showed increased expression of Collagen1a1 mRNA and that the expression of Collagen3a1 and TGFβ1 had tendency to be enhanced in CKO mice, though their increase was not statistically significant (Fig. 3H). We also assessed whether the Runx2 in macrophages have pro-fibrotic property by using bone marrow derived macrophages (BMDMs) and found that Runx2 ablation upregulated the expression of TGFβ1 in BMDMs (Supplementary Fig. S4). To examine the effects of myeloid cell-specific Runx2 deletion on cardiomyocyte death, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining was performed 7 days after MI. TUNEL staining revealed that Runx2 ablation in myeloid cells didn’t affect
cardiomyocyte apoptosis after MI (Supplementary Fig. S5). Moreover, Runx2 CKO mice showed lower survival rates and tended to have higher rates of cardiac rupture compared with control mice (Supplementary Fig. S6). These data suggested that Runx2+ myeloid cells contribute to suppression of adverse cardiac remodeling, proposing the anti-fibrotic function of Runx2 in myeloid cells.

**Runx2+ myeloid cells were involved in post-infarct angiogenesis.** To examine whether Runx2+ myeloid cells influenced vascular function after MI, we assessed capillary density in post-infarct myocardium 14 days after MI using immunohistochemical staining with anti-CD31 antibody (Fig. 4A,B). Though there was no difference in capillary density before MI between control and Runx2-deficient mice (data not shown), capillary density was decreased in Runx2 CKO mice compared with control mice. Moreover, there were no differences in cardiomyocyte surface area between control and Runx2 CKO mice after MI (Fig. 4C,D), proposing that the decrease of capillary density in Runx2 CKO mice was mainly derived from impaired angiogenesis, but not from myocyte hypertrophy.

To address the involvement of Runx2+ myeloid cells in angiogenesis, we analyzed the angiogenic activities of CD11b+ cells. CD11b+ cells were prepared from post-infarct hearts of control and Runx2 CKO mice and cultured for 24 h. HUVECs were cultured in conditioned media from CD11b+ cells from control or Runx2 CKO mice that were exposed to MI. The tube formation assays demonstrated that the conditioned media from Runx2-depleted CD11b+ cells exhibited low angiogenic activity, compared with those from control myeloid cell culture (Fig. 5A–C). To address the mechanisms by which Runx2-expressing myeloid cells induced angiogenesis, RNA-sequence analysis was performed using sorted CD11b+ F4/80+ cells (Fig. 5D,E), and revealed that there was clear difference in the transcriptional profile between Runx2+ and Runx2 CKO macrophages.

---

**Figure 1.** The expression of Runx2 was upregulated in the murine hearts after MI. (A) mRNA expression of Runx2 was analyzed at indicated time-points by quantitative RT-PCR. The results were normalized to that of GAPDH. Data are shown as mean ± SD (n = 5 mice for MI1d, 4d, n = 6 mice for non-MI, n = 8 mice for MI7d, 14d), *P < 0.05, **P < 0.01 vs non-MI by Kruskal–Wallis test followed by Steel test. (B) The heart lysates from WT mice at 1, 4, 7, and 14 days after MI were immunoblotted with anti-Runx2 and anti-GAPDH antibodies. The heart lysates from non-MI mice were used as a control. Representative images are shown. (C) Runx2 expression was quantified. Data shown as mean ± SD (n = 5 mice for MI4d, n = 6 mice for non-MI, MI1d, n = 7 mice for MI7d, n = 8 mice for MI14d), **P < 0.01 vs non-MI by Kruskal–Wallis test followed by Steel test. (D) Masson’s trichrome staining was performed to identify the infarct (+ border) and the remote areas. Representative image is shown. (E) The mRNA expression of Runx2 was quantified 7 days after MI by quantitative RT-PCR. Data shown as mean ± SD (n = 5 mice for MI7d, n = 6 mice for non-MI), **P < 0.01 vs non-MI, remote area by Kruskal–Wallis test following by Steel–Dwass test.
Figure 2. Runx2 was expressed in heart-infiltrating myeloid cells. (A) Paraffin-embedded sections of infarcted myocardium were prepared from the heart 7 days after MI. The sections were stained with anti-Runx2 antibody. Representative images are shown. (bar = 25 μm). (B) Representative flow cytometry plot of leukocytes enriched from MI7d hearts. (C) Frozen sections were prepared from the hearts 7 days after MI. The sections were co-stained with anti-Runx2 and anti-CD68 antibodies. Representative images are shown. Arrows, Runx2+ CD68+ cells; arrow heads, Runx2+ CD68- cells. (bar = 50 μm). (D and E) Flow cytometry analysis of Runx2 expression on F4/80+ CD86+ M1 macrophages (upper) and F4/80+ CD206+ M2 macrophages (lower). CD11b+ myeloid cells were enriched from MI4d (D) or MI7d (E) hearts. Isotype control antibodies were used for positive/negative gate setting.
Interestingly, the expression of pro-angiogenic gene, Cxcl1\(^{21}\), Il-6\(^{22}\) and Hmox1\(^{23}\) was down-regulated, but that of anti-angiogenic gene, Timp3\(^{24}\), Mgp\(^{25}\) and Il-27\(^{26}\) was up-regulated in Runx2-deficient macrophages. These data suggest that Runx2\(^{+}\) myeloid cells could ameliorate post-infarct cardiac remodeling, at least partially, by regulating vascular function.

**Discussion**

Myeloid cells play important roles in cardiac remodeling after myocardial injury\(^{27,28}\). In the present study, we demonstrated that the expression of Runx2 was upregulated in the post-infarct myocardium. Runx2 was mainly expressed in myeloid cells that infiltrated into the border zone. Myeloid cell-specific deletion of Runx2 gene exacerbated cardiac remodeling after MI, associated with the impaired capillary formation. Consistently, the myeloid cells from the infarct myocardium of Runx2-deficient mice exhibited reduced angiogenic activity, compared with control mice, analyzed by tube formation assay in vitro.

Recent advances in osteoimmunology have proposed the concept that bone-related genes are closely associated with immune/inflammatory reactions\(^{29}\). However, it remains to be clarified whether Runx2, a master regulator of osteoblast differentiation\(^{14}\), regulates inflammatory reactions. In cardiovascular diseases, the pathological roles of Runx2 have been reported. For example, the ectopic expression of Runx2 in vascular smooth muscle cells results in vascular calcification in the atherosclerosis\(^{15}\). Here, we demonstrated that Runx2\(^{+}\) myeloid cells infiltrated into post-infarct myocardium and that Runx2 in myeloid cells prevented adverse cardiac remodeling after MI, providing the evidence for the physiological significance of Runx2 as a novel repair/regenerative signaling.

The myocardial expression of Runx2 was upregulated 4–7 days after MI, when macrophages are main infiltrating myeloid cells in post-infarct myocardium. Macrophages are classically classified into 2 subsets, M1 and M2\(^{30}\), and have been considered to have respective roles, such as inflammatory and anti-inflammatory effects. However, it was demonstrated that both M1 and M2 macrophages promote angiogenesis\(^{31}\). In this context, it is interesting that Runx2 was expressed both in M1 and M2 population of macrophages, because myeloid cells from post-infarct Runx2 CKO hearts showed reduced angiogenic activity. Thus, these data propose that the myeloid expression of Runx2 might explain the angiogenic property of M1 and M2 macrophages, as a common feature of these 2 subsets, though further experiments would be needed using M1- and/or M2-specific Runx2 CKO mice.

In Runx2 CKO hearts, capillary density was reduced after MI. Angiogenesis is a critical process of tissue repair after injury and impaired vascular function exacerbates adverse cardiac remodeling, including ventricular rupture\(^{32,33}\). Consistent with the in vivo results, conditioned media from Runx2-null CD11b\(^{+}\) cells failed to promote endothelial tube formation in comparison with control CD11b\(^{+}\) cells, suggesting that Runx2 in myeloid cells regulates post-infarct angiogenesis. To address angiogenesis-related factors responsible for Runx2-mediated regulation of angiogenesis in post-infarct myocardium, we performed RNA-sequence analysis using CD11b\(^{+}\) F4/80\(^{+}\) cells that infiltrated into the hearts after MI and found that the production of pro-angiogenic factors, such as IL-6, CXCL13, and Hmox1, was reduced in Runx2-null CD11b\(^{+}\) F4/80\(^{+}\) cells, while that of some anti-angiogenic...
Figure 3. Myeloid cell-specific Runx2 ablation deteriorated adverse cardiac remodeling after MI. (A) Simplified scheme using Cre-loxP system is shown to generate myeloid cell-specific Runx2-deficient mice. (B, C) Seven days after MI, the sorted CD11b⁺ F4/80⁺ cells lysates from Runx2floflo, a control, and Runx2 CKO mice were immunoblotted with anti-Runx2 and anti-GAPDH antibodies. (B) Representative images are shown. (C) Runx2 expression was quantified. Data are shown mean ± SD (n = 4), **P < 0.01 vs Runx2floflo by Welch’s t-test. (D, E) Ratios of ventricular weight to tibia length (D) and lung weight to tibia length (E) were calculated 14 days after MI. Data were shown as mean ± SD (n = 11 for Runx2floflo mice, n = 13 for Runx2 CKO mice), *P < 0.05, **P < 0.01 vs Runx2floflo by Mann Whitney’s U-test. (F, G) Heart sections were prepared from Runx2floflo and Runx2 CKO mice 14 days after MI and stained with Masson’s trichrome method. (F) Representative images are shown. (G) The ratio of fibrotic area to LV area was quantitatively estimated. Data are shown as mean ± SD (n = 11 for Runx2floflo mice, n = 14 for Runx2 CKO mice), *P < 0.01 vs Runx2floflo by Student’s t-test. (H) Quantitative RT-PCR was performed for collagen1a1, collagen3, and Tgfβ1 7 days after MI. The results were normalized to that of GAPDH. Data are shown mean ± SD (n = 4 for Runx2floflo mice, n = 6 for Runx2 CKO mice), *P < 0.05 vs Runx2floflo by Mann Whitney’s U-test.
factors, such as Mgp1, Timp3, and IL-27, was increased, proposing the hypothesis that the combined effects of reduced pro-angiogenic and enhanced anti-angiogenic activities resulted in the impaired angiogenesis. Thus, it could be suggested that Runx2+ myeloid cells could ameliorate post-infarct cardiac remodeling, at least partially, by regulating vascular functions.

This study has some limitations. First, we exclusively used male mice throughout this study to avoid the effect of estrogen cycle. According to the previous report, the biological function of macrophages may be dependent on sex difference during cardiac remodeling. Further studies are needed to determine the function of Runx2-expressing myeloid cell in female during cardiac remodeling. Another limitation is the hematological difference of peripheral blood at baseline. In the present study, lymphocytes were decreased in number in Runx2 CKO mice at baseline. Though further study would be required to elucidate how lymphocytes decreased in Runx2 CKO mice, it is unlikely that the post-infarct cardiac remodeling was exacerbated in Runx2 CKO mice due to

### Table 1.
Cardiac functions of Runx2fl/fl and Runx2 CKO mice after MI. LVIDd = left ventricular internal dimension at diastole; LVIDs = left ventricular internal dimension at systole; FS = fractional shortening. Data are shown as mean ± SD (Runx2fl/fl mice: n = 5, Runx2 CKO mice: n = 6). *P < 0.05 vs Runx2fl/fl at Day14 by Student’s t-test, ††P < 0.01 vs Day0 by Dunnett test.

|          | Day0 | Day7 | Day14 |
|----------|------|------|-------|
|          | fl/fl | CKO  | fl/fl | CKO  | fl/fl | CKO  |
| LVIDd (cm) | 0.37 ± 0.02 | 0.37 ± 0.02 | 0.43 ± 0.03 | 0.47 ± 0.08 | 0.48 ± 0.02†† | 0.50 ± 0.05†† |
| LVIDs (cm) | 0.17 ± 0.01 | 0.17 ± 0.02 | 0.25 ± 0.02 | 0.30 ± 0.08 | 0.31 ± 0.01†† | 0.36 ± 0.03†† |
| FS (%)    | 54.0 ± 3.1 | 53.2 ± 2.8 | 41.9 ± 3.7 | 37.4 ± 5.1 | 34.7 ± 4.5†† | 29.0 ± 2.8†† |

**Figure 4.** Capillary density was reduced in the post-infarct myocardium of Runx2 CKO mice. (A) Heart sections were prepared from Runx2fl/fl and Runx2 CKO mice 14 days after MI. The sections were stained with anti-CD31 antibody. Representative images are shown. (B) Capillary density was quantitatively estimated. Data are shown as mean ± SD (n = 11 for Runx2fl/fl mice, n = 14 for Runx2 CKO mice), *P < 0.05 vs Runx2fl/fl by Student’s t-test. (C) Heart sections were prepared from Runx2fl/fl and Runx2 CKO mice 14 days after MI. The sections were stained with wheat germ lectin conjugated with fluorescein isothiocyanate. Representative images are shown. (D) Cross-sectional area was quantitatively estimated. Data were shown as mean ± SD (n = 4 for Runx2fl/fl mice, Runx2 CKO mice).
Figure 5. Runx2 ablation impaired angiogenic activity of infiltrated myeloid cells following MI. (A–C) CD11b+ cells were prepared from Runx2fl/fl and Runx2 CKO hearts 7 days after MI and cultured for 24 h. Conditioned media from CD11b+ myeloid cells of Runx2fl/fl and Runx2 CKO were added to HUVECs. After 8 h, tube formation of HUVECs was evaluated. (A) Representative images of tube formation are shown. The number of nodes (B) and branches (C) was measured. Data are shown as mean ± SD (n = 4 for each condition) *P< 0.05 vs Runx2fl/fl by student’s t-test. (D, E) CD11b+ F4/80+ macrophages were isolated from hearts of Runx2fl/fl and Runx2 CKO mice at 7 days after MI. Total mRNA was extracted from the cells and RNA-sequence was performed (n = 2 in each group). Pro-angiogenic factors were indicated by blue letters, while anti-angiogenic factors by red (D) Heat map shows the gene with > 2.0-fold change between Runx2fl/fl and Runx2 CKO with a P-value of < 0.05. (E) Volcano plots represent angiogenic gene expression compared Runx2fl/fl vs Runx2 CKO.
the decrease in lymphocytes, because Rag1−/− mice, which lack lymphocytes, had significantly smaller infarct size than control mice after MI33 unlike Runx2 CKO mice.

In conclusion, myeloid cell-specific ablation of Runx2 gene exacerbated cardiac remodeling after MI, indicating that Runx2+ myeloid cells play important roles in cardioprotection. Thus, the modulation of Runx2+ cells could be a novel therapeutic strategy against HF.

Methods
Animals. All animal experiments were carried out under the guidelines set by the Institutional Animal Care and Use Committees at Osaka University and RIKEN Kobe Branch. All the animal experiments in this study conformed to the Guide for the Care and Use of Laboratory Animals, Eighth Edition, updated by the US National Research Council Committee in 2011 and The Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines, and were approved by Animal Experimentation Committee of Osaka University and Institutional Animal Care and Use Committee of RIKEN Kobe Branch. At the endpoints of all experiments, mice were anesthetized by inhalation of an overdose of isoflurane and the hearts were harvested. All efforts were made to minimize suffering.

Generation of myeloid cell-specific Runx2 deficient mice. Based on the previous report36, the targeting vector with loxP sites flanking exon3 in the mouse Runx2 gene was constructed to generate Runx2-floxed mice (Accession No. CDB0970K: http://www2.cst.riken.jp/arg/mutant%20mice%20list.html). Heterozygous Runx2-floxed mice were crossed with transgenic mice expressing LysM-Cre recombinase, generously gifted by Dr. Kiyoshi Takeda, Osaka University. The obtained heterozygous knockout mice were crossed with each other to develop homozygous Runx2-deficient (Runx2 CKO) mice. Homozygous Runx2-floxed mice (fl/fl) were used as control. The primers used for genotyping of Runx2-floxed mice are shown as follows: Runx2 forward, 5’-GTC GTGACCCGAGAAGTG-3’; reverse, 5’-GAAGTTAACAGCTGCGTAG-3’. The PCR reaction produces 613 bp band for WT allele and 819 bp band for the floxed allele.

Counting leukocyte fraction. Peripheral blood was harvested from Runx2fl/fl and Runx2 CKO mice at baseline. For inhibition of coagulation, EDTA-2 K (FUJIFILM, 340–01511) was added at a final concentration of 1.5 mg/mL. The analysis was contracted to BioSafety Research Center Inc (Japan).

Myocardial infarction model. Myocardial infarction (MI) was generated by coronary artery ligation in C57BL/6 male mice (Japan SLC) and Runx2 CKO male mice (8–14-week-old) as previously described35.

Quantitative RT-PCR. Total RNA was prepared from hearts at various time points after coronary ligation. Total RNA (1 μg) was subjected to first-strand cDNA synthesis using the oligo-deoxythymidine standard primer. The expression of Runx2, Collagen1a1, Collagen3a1, Tgfβ1 and glyceraldehyde 3-phosphate dehydrogenase (Gapdh) gene was quantified by quantitative RT-PCR using the SYBR Green kit (Applied Biosystems, 4385612). The primers used in this study are shown as follows: mouse Runx2 forward, 5’-CATCACCATCTCCAGGAAGCG-3’; reverse, 5’-GAGGGCCATCCAAGCTCTTC-3’, mouse Gapdh forward, 5’-CCGGAAATGTGAGAACTACTC-3’; reverse, 5’-GAGGAACTCTGCTGCTGCG-3’, mouse Collagen1a1 forward, 5’-GGAAGTGTGTGTCGCCCTTCG-3’; reverse, 5’-GCCCTCTAGTGACCCGTGTC-3’. The primers used for genotyping of Runx2-floxed mice are shown as follows: Runx2 forward, 5’-ATGCCCAACAGGCTTCTCACA-3’, reverse, 5’-CCCCAGGTTACACCTTTCCTCC-3’, mouse Tgfβ1 forward, 5’-CTCCCGTGTTCTTAGTCG3-3’. The reaction produces 613 bp band for WT allele and 819 bp band for the floxed allele.

Immunoblotting. Proteins from MI hearts or infiltrating cells were separated by SDS-PAGE and transferred to polyvinylidene difluoride membrane (Merck Millipore, IPVH00010). The membrane was blocked with 2% skim milk for 1 h, followed by incubation with rabbit anti-Runx2 (Cell Signaling Technology, #12556, 1/1000) and mouse anti-GAPDH (Merck Millipore, #MAB374, 1/1000) antibodies overnight at 4 °C. After primary antibody reaction, membranes were incubated with HRP-conjugated anti rabbit IgG (Cell Signaling Technology, #7074, 1/2000) or HRP-conjugated anti mouse IgG (Jackson ImmunoResearch, 115–035-062, 1/2000) for 1 h at room temperature. Chemiluminescence reagent, Chemi-lumi one super, (Nacalai tesque, 02230–30) were used for detection, and bands were developed using a LAS4010 Imaging system (Cytiva).

Histological estimation of cardiac fibrosis. Cardiac fibrosis was histologically estimated 14 days after coronary ligation. The frozen sections (5-μm-thick) were prepared from the portion ~ 400 μm distal to the ligation point and stained with Masson’s trichrome. Photomicrographs were taken, and the areas were measured using Image J (National Institutes of Health). The fibrotic area was calculated as a percentage of LV area by a researcher who was blinded to the experimental protocol.

Immunofluorescent microscopic analyses. Frozen sections (5-μm-thick) were prepared 7 days after coronary ligation. The sections were fixed with 4% paraformaldehyde (PFA) and blocked with 3% bovine serum albumin (BSA) in Tris-buffered saline containing 0.1% Triton X-100. Then, the sections were stained with rabbit anti-Runx2 (Cell Signaling Technology, #12556, 1/1000), goat anti-periostin (Santa Cruz Biotechnology, sc-49480, 1/100) and rat anti-Collagen1 (Invitrogen, #14–0061-80, 1/100) antibodies overnight at 4 °C. Alexa Fluor 488-conjugated goat anti-rat IgG (Invitrogen, A-11006, 1/200), Alexa Fluor 488-conjugated donkey anti-goat IgG (Invitrogen, A-11055, 1/200) and Alexa Fluor 546-conjugated donkey anti-rabbit IgG (Invitrogen, A-10040,
were analyzed using FlowJo software (Tree Star). Flow cytometric analysis was performed with FACS AriaII (BD Biosciences) and data analysis was performed using FoxP3/Transcription Factor Staining Buffer set (Invitrogen, #00-5523-00) according to manufacturer's protocol. Isotype Ctrl antibody (BioLegend, #400523) were used for negative control antibodies. Intracellular Runx2 labeling (BioLegend, #400507), APC Rat IgG2a, κ Isotype Ctrl antibody (BioLegend, #400511), and APC/Cy7 Rat IgG2a, κ Isotype Ctrl antibody (BioLegend, #400505), PE Rat IgG2a, κ Isotype Ctrl antibody (BioLegend, #400510) were attached to the magnet for 8 min and cell population attached to the wall of the column was collected in PBS (BD Biosciences, #552362), Streptavidin Particles Plus-DM (BD Biosciences, #557812) was added five times for 30 min. FITC Rat IgG2a, κ Isotype Ctrl antibody (BioLegend, #400505), PE Rat IgG2a, κ Isotype Ctrl antibody (BioLegend, #400510) and rabbit anti-Runx2 antibody (Cell signaling Technology, #12556, 1/100) were used for 30 min on ice. The column of the cell suspension was attached to the magnet for 8 min and cell population attached to the wall of the column was collected in PBS / 3% fetal bovine serum (FBS). Erythrocytes were removed from the cells using Lysing buffer (BD Biosciences, #555899). After centrifugation, the pellet was resuspended in 40 / 80% Percoll buffer layers (Cytiva, 17-0891-02) and the leukocyte-rich fraction was collected from the interface between 40 and 80% Percoll buffer by 25-min-centrifugation, followed by the blockade of Fc receptors. Biotinylated anti-CD11b antibody (BioLegend, #101203) was added to cell suspension (1 µl / 1 × 10^6 cells) and incubated for 30 min on ice. After centrifugation, the cells were resuspended in BD IMag Buffer (BD Biosciences, #552362), Streptavidin Particles Plus-DM (BD Biosciences, #557812) was added five times for 30 min on ice. The amount of biotin anti-CD11b antibody, then incubated for 30 min on ice. The column of the cell suspension was attached to the magnet for 8 min and cell population attached to the wall of the column was collected in PBS / 3% FBS so that the “positive” fraction could be collected. Consistent with previous report, Percoll and MACS cell separation enriched leukocytes to a high purity of 98%.

**Preparation of CD11b+ cells by Magnetic activated cell sorting system.** Infarcted hearts were harvested and washed with PBS, perfused with 0.025% collagenase solution [0.0125% collagenase type B (Roche), 0.0125% collagenase type D (Roche), and 0.002% collagenase type XIV (Sigma-Aldrich)] and minced into pieces. The pieces of heart tissue were digested with 0.1% collagenase solution [0.05% collagenase type B (Roche), 0.05% collagenase type D (Roche), and 0.002% collagenase type XIV (Sigma-Aldrich)] at 37 °C. Then the cells were filtered through a 70 µm cell strainer and suspended in PBS / 3% fetal bovine serum (FBS). Erythrocytes were removed from the cells using Lysing buffer (BD Biosciences, #555899). After centrifugation, the pellet was resuspended in 40 / 80% Percoll buffer layers (Cytiva, 17-0891-02) and the leukocyte-rich fraction was collected from the interface between 40 and 80% Percoll buffer by 25-min-centrifugation, followed by the blockade of Fc receptors. Biotinylated anti-CD11b antibody (BioLegend, #101203) was added to cell suspension (1 µl / 1 × 10^6 cells) and incubated for 30 min on ice. After centrifugation, the cells were resuspended in BD IMag Buffer (BD Biosciences, #552362), Streptavidin Particles Plus-DM (BD Biosciences, #557812) was added five times for 30 min on ice. FITC Rat IgG2a, κ Isotype Ctrl antibody (BioLegend, #400505), PE Rat IgG2a, κ Isotype Ctrl antibody (BioLegend, #400510), APC Rat IgG2a, κ Isotype Ctrl antibody (BioLegend, #400523) were used for negative control antibodies. Intracellular Runx2 labeling was performed using FoxP3/Transcription Factor Staining Buffer set (Invitrogen, #00-5523-00) according to manufacturer's protocol. Flow cytometric analysis was performed with FACS AriaII (BD Biosciences) and data were analyzed using FlowJo software (Tree Star).

**Gravimetric study.** The hearts and lungs were harvested and washed in phosphate buffered saline (PBS). The weight of these organs was measured using an electronic balance and normalized to the tibia length or body weight.

**Analysis of cardiac function.** Two-dimensional and motion mode (M-mode) transthoracic echocardiography was performed using an iE33 model equipped with a 15-MHz transducer (Philips). Echocardiographic measurements were taken in M-mode. Left ventricular internal diameters at end-diastole (LVIDd), left ventricular internal diameters at end-systole (LVIDs), and fractional shortening (FS) were calculated with the established standard equation. The investigator was blinded to the identity of the mice for analysis.

**Cell culture.** BMDMs were isolated from femurs of adult RUNX2fl/fl or RUNX2 CKO mice and differentiated into macrophages using RPMI1640 supplemented with 20 mM recombinant mouse M-CSF (R&D systems, 416-ML-010) containing 10% FBS and 1% penicillin-streptomycin at 37 °C, 5% CO2 for 7 days. BMDMs (5.0 × 10^6 cells/mL) were seeded 6-well culture plates. BMDMs were stimulated with 100 ng/mL LPS (Sigma-Aldrich, O111:B4) for 24 h, and then, total RNA was extracted.
Tube formation assay. 10^4 human umbilical vein endothelial cells (HUVEC) in 50 μL 2% FBS/EGM2 basal medium (Lonza, CC-3156) were seeded into 96-well plates which were treated with 50 μL extracellular matrix solution (Abcam, ab204726) for 1 h at 37 °C. After 8 h incubation with conditioned media, the cells were evaluated for a number of nodes and branches.

RNA-sequencing analysis. Total RNA was prepared from sorted CD11b^+ F4/80^+ macrophages from post-infarct myocardium (2–5 × 10^6 cells/each population) using the Qiazol (QIAGEN) and miRNeasy Mini Kit (QIAGEN). cDNA was generated using a SMART-Seq HT Kit (Clontech). Each library was prepared using Nextera XT (Illumina) according to the manufacturer's instructions. Sequencing was performed on an Illumina HiSeq 2500 platform in a 75-base single-end mode. Illumina Casava 2.1 platform was used for basecalling. Sequenced reads were mapped to the mouse reference genome sequence (mm10) using TopHat ver.2.0.13 in combination with Bowtie2 ver.2.2.3 and SAMtools ver.0.1.19. The fragments per kilobase of exon per million mapped fragments (FPKMs) was calculated using Cuffnorm ver.2.2.1. Volcano plots were created using Biopepsi^9.

Statistical analysis. Data are presented as mean ± SD. The χ^2 goodness of fit test was first used to determine data normality, and the F test was used to determine equal variance. If the data passed the evaluation of normality, statistical significance was determined by Student’s or Welch’s t-test for 2 groups, and One-way analysis of variance (ANOVA) with the Dunnett test for multiple comparisons. Nonparametric tests, such as Kruskal-Wallis test, steels test, or Mann-Whitney U test were used when the data displayed abnormal distribution. Survival curves were obtained by the Kaplan-Meier method and compared by the log-rank test. Differences were considered statistically significant when the calculated (two-tailed) P-value was < 0.05.

Data availability
The data that support the findings of this study are available from the corresponding authors, Y. F., upon reasonable request.

Received: 22 November 2021; Accepted: 23 September 2022
Published online: 05 October 2022

References
1. Pfeffer, M. A. & Braunwald, E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81, 1161–1172. https://doi.org/10.1161/01.cir.81.11.1161 (1990).
2. Opie, L. H., Commerford, P. J., Gersh, B. J. & Pfeffer, M. A. Controversies in ventricular remodelling. J Am Coll Cardiol 36, 356–367. https://doi.org/10.1016/S0735-1097(00)00035-6 (2000).
3. Gajarsa, J. J. & Kloner, R. A. Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev 16, 13–21. https://doi.org/10.1007/s10759-010-9181-y (2011).
4. Vilahur, G. et al. Molecular and cellular mechanisms involved in cardiac remodeling after acute myocardial infarction. J Mol Cell Cardiol 50, 522–533. https://doi.org/10.1016/j.yjcc.2010.12.021 (2011).
5. Rouleau, J. L. et al. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol 22, 390–398. https://doi.org/10.1016/S0735-1097(93)90014-X (1993).
6. Yancy, C. W. et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American college of cardiology foundation/American heart association task force on practice guidelines. J Am Coll Cardiol 62, e147-239. https://doi.org/10.1016/j.jacc.2013.05.019 (2013).
7. van Amerongen, M. J., Harmsen, M. C., van Rooijen, N., Petersen, A. H. & van Lynden, M. J. Macrophage depletions impairs wound healing and increases left ventricular remodeling after myocardial injury in mice. Am J Pathol 170, 818–829. https://doi.org/10.1016/j.ajpath.2007.060547 (2007).
8. Leor, J. et al. Ex vivo activated human macrophages improve healing, remodeling, and function of the infarcted heart. Circulation 114, 194-100. https://doi.org/10.1161/circulationaha.105.000331 (2006).
9. White, D. A. et al. Differential roles of cardiac and leukocyte derived macrophage migration inhibitory factor in inflammatory responses and cardiac remodelling post myocardial infarction. J Mol Cell Cardiol 69, 32–42. https://doi.org/10.1016/j.yjcc.2014.01.015 (2014).
10. Lorcher, H. et al. Myocardial healing requires Reg3β-dependent accumulation of macrophages in the ischemic heart. Nat Med 21, 353–362. https://doi.org/10.1038/nm.3816 (2015).
11. Kumagai, S. et al. Myeloid cell-derived LRG attenuates adverse cardiac remodelling after myocardial infarction. Cardiovasc Res 109, 272–282. https://doi.org/10.1093/cvr/cvr273 (2016).
12. Frantzi, S. & Nahrendorf, M. Cardiac macrophages and their role in ischaemic heart disease. Cardiovasc Res 102, 240–248. https://doi.org/10.1093/cvr/cvr025 (2014).
13. Jung, M. et al. IL-10 improves cardiac remodeling after myocardial infarction by stimulating M2 macrophage polarization and fibroblast activation. Basic Res Cardiol 112, 33. https://doi.org/10.1007/s00395-017-0622-5 (2017).
14. Oldberg, A., Fransen, A. & Heinegard, D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A 83, 8819–8823. https://doi.org/10.1073/pnas.83.23.8819 (1986).
15. Trueblood, N. A. et al. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res 88, 1080–1087. https://doi.org/10.1161/01.hsr.0000090842 (2001).
16. Stawowy, P. et al. Increased myocardial expression of osteopontin in patients with advanced heart failure. Eur J Heart Fail 4, 139–146. https://doi.org/10.1016/s1388-9842(01)00237-9 (2002).
17. Okamoto, H. et al. Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol: Japanese chronic heart failure (J-CHF) study. Int J Cardiol 164, 238–244. https://doi.org/10.1016/j.ijcard.2012.11.051 (2013).
18. Otto, F. et al. Cb61, a candidate gene for skeletal dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89, 765–771. https://doi.org/10.1016/s0092-8674(00)08259-7 (1997).
19. Sun, Y. et al. Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification. Circ Res 111, 543–552. https://doi.org/10.1161/CIRCRESAHA.111.267237 (2012).
20. Nahrendorf, M., Fitter, M. J. & Swirski, F. K. Monocytes: Protagonists of innate inflammation and repair after myocardial infarction. Circulation 121, 2437–2445. https://doi.org/10.1161/CIRCRESAHA.109.916346 (2010).
21. Tsai, C. H. et al. CXCL13/CXCR5 axis facilitates endothelial progenitor cell homing and angiogenesis during rheumatoid arthritis progression. *Cell Death Dis* **12**, 846. https://doi.org/10.1038/s41419-021-04136-2 (2021).

22. Fan, Y. et al. Interleukin-6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro. *J Cereb Blood Flow Metab* **28**, 90–98. https://doi.org/10.1038/sj.jcbfm.9600509 (2008).

23. Grochot-Przeczek, A. et al. Heme oxygenase-1 is required for angiogenic function of bone marrow-derived progenitor cells: Role in therapeutic revascularization. *Antioxid Redox Signal* **20**, 1677–1692. https://doi.org/10.1089/ars.2013.5426 (2014).

24. Qi, J. H. & Anand-Apte, B. Tissue inhibitor of metalloproteinase-3 (TIMP3) promotes endothelial apoptosis via a caspase-independent mechanism. *Apoptosis* **20**, 523–534. https://doi.org/10.1007/s10495-014-1076-y (2015).

25. Sharma, B. & Albig, A. R. Matrix Gla protein reinforces angiogenic resolution. *Microvasc Res* **85**, 24–33. https://doi.org/10.1016/j.mvr.2012.10.005 (2013).

26. Shimizu, M. et al. Antiangiogenic and antitumor activities of IL-27. *J Immunol* **176**, 7317–7324. https://doi.org/10.4049/jimmunol.176.12.7317 (2006).

27. Shinagawa, H. & Frantz, S. Cellular immunity and cardiac remodeling after myocardial infarction: Role of neutrophils, monocytes, and macrophages. *Carr Heart Fail Rep* **12**, 247–254. https://doi.org/10.4118/cshfr.2011.39520 (2015).

28. Tourki, B. & Halade, G. Leukocyte diversity in resolving and nonresolving mechanisms of cardiac remodeling. *FASEB J* **31**, 4226–4239. https://doi.org/10.1096/fj.201700109R (2017).

29. Okamoto, K. et al. Osteoimmunology: The conceptual framework unifying the immune and skeletal systems. *Physiol Rev* **97**, 1295–1349. https://doi.org/10.1152/physrev.00036.2016 (2017).

30. Murray, P. J. et al. Macrophage activation and polarization: Nomenclature and experimental guidelines. *Immunity* **41**, 14–20. https://doi.org/10.1016/j.immuni.2014.06.008 (2014).

31. Jetten, N. et al. Local delivery of polarized macrophages improves reperfusion recovery in a mouse hind limb ischemia model. *PLoS ONE* **8**, e68811. https://doi.org/10.1371/journal.pone.0068811 (2013).

32. Oka, T., Akazawa, H., Naito, A. T. & Komuro, I. Angiogenesis and cardiac hypertrophy: Maintenance of cardiac function and causative roles in heart failure. *Circ Res* **114**, 565–571. https://doi.org/10.1161/CIRCRESAHA.114.300507 (2014).

33. Cao, D. J. et al. Cytosolic DNA sensing promotes macrophage transformation and governs myocardial ischemic injury. *Circulation* **137**, 2613–2634. https://doi.org/10.1161/CIRCULATIONAHA.117.031046 (2018).

34. Chen, K. E., Lainez, N. M. & Coss, D. Sex differences in macrophage responses to obesity-mediated changes determine migratory and inflammatory traits. *Circulation* **134**, 141–153. https://doi.org/10.1161/CIRCULATIONAHA.120.049253 (2021).

35. Yang, Z. et al. Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes. *Circulation* **114**, 2056–2064. https://doi.org/10.1161/CIRCULATIONAHA.106.649244 (2006).

36. Qin, X. et al. Runx2 is essential for the transdifferentiation of chondrocytes into osteoblasts. *PLoS Genet* **16**, e1009169. https://doi.org/10.1371/journal.pgen.1009169 (2020).

37. Obana, M. et al. Therapeutic activation of signal transducer and activator of transcription 3 by interleukin-11 ameliorates cardiac fibrosis after myocardial infarction. *Circ Res* **114**, 565–571. https://doi.org/10.1161/CIRCULATIONAHA.110.893677 (2010).

38. Pan, J. & Wan, J. Methodological comparison of FACS and MACS isolation of enriched microglia and astrocytes from mouse brain. *PLoS ONE* **16**, e0215551. https://doi.org/10.1371/journal.pone.0215551 (2021).

Acknowledgements
We thank Hiroyuki Nakayama for his precious advice.

Author contributions
M.T.: Conceptualization, Data curation, Formal analysis, Investigation, Writing; K.M.: Conceptualization, Data curation, Formal analysis, Investigation, Writing; M.A.: Data curation, Formal analysis, Investigation; S.K.: Data curation, Formal analysis, Investigation, Writing; Y.F.: Conceptualization, Data curation, Formal analysis, Investigation, Writing, Supervision.

Funding
This work was partially supported by MEXT/JSPS KAKENHI Grants 26293054, 18H02603 and 20K21575, The Bayer Scholarship for Cardiovascular Research and Platform Project for Supporting Drug Discovery and Life Science Research (Basic for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED under Grant Number JP21am0101084, JP21am0101123, 22ama121052, and 22ama121054.

Competing interests
The authors declare no competing interests.

Additional information
**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-21202-7.

**Correspondence** and requests for materials should be addressed to M.O. or Y.F.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
